{
    "clinical_study": {
        "@rank": "153137", 
        "arm_group": [
            {
                "arm_group_label": "Suboxone sublingual film 8/2", 
                "arm_group_type": "Experimental", 
                "description": "Participants took a single dose of Suboxone sublingual film 8/2 either on Day 0 or Day 1, depending on the how each participant was randomized in this cross-over study."
            }, 
            {
                "arm_group_label": "Zubsolv sublingual tablets 5.7/1.4", 
                "arm_group_type": "Active Comparator", 
                "description": "Participants took a single dose of Zubsolv sublingual tablets 5.7/1.4 either on Day 0 or Day 1, depending on the how each participant was randomized in this cross-over study."
            }
        ], 
        "brief_summary": {
            "textblock": "The primary objective of this study is to compare overall patient preference for either\n      Suboxone\u00ae sublingual film 8/2 or Zubsolv\u00ae sublingual tablets 5.7/1.4.  Suboxone sublingual\n      film 8/2 contains 8mg buprenorphine and 2mg naloxone. Zubsolv sublingual tablets contain 5.7\n      mg buprenorphine and 1.4 mg naloxone.  Both interventions act as a substitute for opiate\n      drugs like heroin, morphine or oxycodone and help withdrawal from opiate drugs over a period\n      of time."
        }, 
        "brief_title": "Usability of Zubsolv Sublingual Tablets 5.7/1.4 to Suboxone Sublingual Film 8/2 In Buprenorphine/Naloxone Treated Opioid Dependent Population", 
        "completion_date": {
            "#text": "January 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Opioid Dependence", 
        "condition_browse": {
            "mesh_term": "Opioid-Related Disorders"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  currently on a single daily dose of 8/2 of Suboxone or generic equivalent, or 5.7/1.4\n             mg Zubsolv for treatment of opioid dependence that has been medically confirmed.\n\n          -  in good general health with no specific contraindication for treatment with\n             buprenorphine or naloxone.\n\n          -  the ability to understand, sign and date written consent and Health Information\n             Portability and Accountability Act (HIPAA) authorization forms, which must be\n             obtained prior to any study related procedures being completed.\n\n          -  Female subjects must be postmenopausal for at least 2 years, surgically sterile (i.e.\n             tubal ligation, hysterectomy, or bilateral ovariectomy), or practicing an effective\n             method of contraception during the study with one of the following methods:  oral\n             contraception,  intrauterine device (IUD), abstinence, contraceptive injections,\n             conscientious use of a diaphragm or condoms and spermicidal foam, systemic (implant)\n             contraception or partner has had a vasectomy.\n\n        Exclusion Criteria:\n\n          -  Subject is taking other opioids (other than buprenorphine/naloxone) that may\n             interfere with the study evaluations or compromise the safety of the subject.\n\n          -  Subject is not able to read or have other impairments that may prevent completion of\n             questionnaires or other study evaluations\n\n          -  Subject has open sores present in the oral cavity.\n\n          -  Subject has participated in any previous clinical testing involving investigational\n             drug within the 4 weeks prior to study start.\n\n          -  Subject is pregnant, lactating or planning a pregnancy\n\n          -  Subject is currently participating in any other type of clinical testing.\n\n          -  Subject has a medical condition that in the Investigator's opinion could affect the\n             taste assessments required by the study\n\n          -  Subject is judged by the Investigator after reviewing medical history to be\n             unsuitable for any other reason that may either place the subject at increased risk\n             during participation or interfere with the interpretation of the study outcomes."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "33", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 15, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02038790", 
            "org_study_id": "RBP-OSZ1"
        }, 
        "intervention": [
            {
                "arm_group_label": "Suboxone sublingual film 8/2", 
                "description": "A single Suboxone sublingual film strip containing 8mg buprenorphine and 2mg naloxone taken sublingually on either Day 0 or Day 1, depending on randomized treatment arm assignment.  Study drug will be administered by designated qualified study personnel at the site in the morning prior to 9:00 a.m. under fasting conditions.", 
                "intervention_name": "Suboxone Sublingual Film", 
                "intervention_type": "Drug", 
                "other_name": [
                    "buprenorphine", 
                    "naloxone"
                ]
            }, 
            {
                "arm_group_label": "Zubsolv sublingual tablets 5.7/1.4", 
                "description": "A single Zubsolv sublingual tablet containing 5.7mg buprenorphine and 1.4mg naloxone taken sublingually on either Day 0 or Day 1, depending on randomized treatment arm assignment. Study drug will be administered by designated qualified study personnel at the site in the morning prior to 9:00 a.m. under fasting conditions.", 
                "intervention_name": "Zubsolv sublingual tablets", 
                "intervention_type": "Drug", 
                "other_name": [
                    "buprenorphine", 
                    "naloxone"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Buprenorphine", 
                "Analgesics, Opioid", 
                "Naloxone"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "opioid dependence", 
            "buprenorphine/naloxone"
        ], 
        "lastchanged_date": "January 15, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "St Petersburg", 
                    "country": "United States", 
                    "state": "Florida", 
                    "zip": "33714"
                }, 
                "name": "Hill Top Research"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Single Center, Randomized, 2 Way Cross-Over, Phase 4 Study Comparing Usability of Zubsolv Sublingual Tablets 5.7/1.4 to Suboxone Sublingual Film 8/2 Including Ease of Use, Taste Preference, Dissolution Time, Desire to Abuse, and Overall Acceptance In Buprenorphine/Naloxone Treated Opioid Dependent Population", 
        "overall_official": {
            "affiliation": "Hill Top Research", 
            "last_name": "John Murray, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Overall Intervention Preference As Recorded by Participants", 
            "safety_issue": "No", 
            "time_frame": "Day 0 (post treatment), Day 1"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02038790"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Taste preference including taste acceptability as Assessed by Participants", 
                "safety_issue": "No", 
                "time_frame": "Days 0-1"
            }, 
            {
                "measure": "Participant Desire to abuse as Assessed by Participants", 
                "safety_issue": "No", 
                "time_frame": "Days 0-1"
            }, 
            {
                "measure": "Dissolution time of Intervention as Recorded by a Trained Observer", 
                "safety_issue": "No", 
                "time_frame": "Days 0-1"
            }, 
            {
                "description": "An overall assessment of administration, portability, and packaging of the two test articles", 
                "measure": "Overall acceptability of Intervention as Assessed by Participants", 
                "safety_issue": "No", 
                "time_frame": "Days 0-1"
            }, 
            {
                "measure": "Ease-of-use As Assessed by Participants", 
                "safety_issue": "No", 
                "time_frame": "Days 0-1"
            }, 
            {
                "measure": "Change from Baseline in Subject Opiate Withdrawal Scale (SOWS)", 
                "safety_issue": "No", 
                "time_frame": "Day 0 prior to dosing, end of Day 0 (post dose), end of Day 1 (post dose)"
            }
        ], 
        "source": "Reckitt Benckiser Pharmaceuticals Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Reckitt Benckiser Pharmaceuticals Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}